Palmitoylethanolamide (PEA)
What studies of Palmitoylethanolamide (PEA) found
At a glance, by condition
Long COVID: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty): 3 of 5 findings are D.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Palmitoylethanolamide (PEA) for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Palmitoylethanolamide (PEA) · Long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Depression1 study · 57 people took Palmitoylethanolamide (PEA) Improvement C
Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).
Compared with another group, not randomised98 in the study · 3 months · 600 mg, twice a day
Depression improved more than in the comparison group.
The evidence is very uncertain about the effect of palmitoylethanolamide (PEA) on depression in long COVID. Improvement · very low certainty C
- Serious risk of bias (ROBINS-I)
See the 1 study
-
- People in the study
- 98 in the study
- Dose
- 600 mg, twice a day
- Outcome
- ΔZSDS Zung Self-Rating Depression Scale
- Effect
- better
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age, sex and neuropsychiatric status prior to therapy; separate models also included SARC-F, FSS, VAS-general, VAS-pain and ZSDS at 3 months
m/umPEA treatment emerged as being a significant predictor of global improvement independently of age, sex and neuropsychiatric status prior to therapy
- Selection of participants
- Moderate. comparison group: Non-randomised; patients who refused m/umPEA served as controls
Patients who chose to receive the proposed treatment were compared to those who did not, thereby constituting the control group.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Missing data were not imputed; no per-arm counts of missing data reported
Missing data were not imputed.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Fatigue1 study · 57 people took Palmitoylethanolamide (PEA) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.
Compared with another group, not randomised98 in the study · 3 months · 600 mg, twice a day
No clear difference in fatigue.
The evidence is very uncertain about the effect of palmitoylethanolamide (PEA) on fatigue in long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
See the 1 study
-
- People in the study
- 98 in the study
- Dose
- 600 mg, twice a day
- Outcome
- ΔSARC-F Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls questionnaire
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age, sex and neuropsychiatric status prior to therapy; separate models also included SARC-F, FSS, VAS-general, VAS-pain and ZSDS at 3 months
m/umPEA treatment emerged as being a significant predictor of global improvement independently of age, sex and neuropsychiatric status prior to therapy
- Selection of participants
- Moderate. comparison group: Non-randomised; patients who refused m/umPEA served as controls
Patients who chose to receive the proposed treatment were compared to those who did not, thereby constituting the control group.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Missing data were not imputed; no per-arm counts of missing data reported
Missing data were not imputed.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Pain1 study · 57 people took Palmitoylethanolamide (PEA) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.
Compared with another group, not randomised98 in the study · 3 months · 600 mg, twice a day
No clear difference in pain.
The evidence is very uncertain about the effect of palmitoylethanolamide (PEA) on pain in long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
See the 1 study
-
- People in the study
- 98 in the study
- Dose
- 600 mg, twice a day
- Outcome
- ΔVAS pain visual analog scale
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age, sex and neuropsychiatric status prior to therapy; separate models also included SARC-F, FSS, VAS-general, VAS-pain and ZSDS at 3 months
m/umPEA treatment emerged as being a significant predictor of global improvement independently of age, sex and neuropsychiatric status prior to therapy
- Selection of participants
- Moderate. comparison group: Non-randomised; patients who refused m/umPEA served as controls
Patients who chose to receive the proposed treatment were compared to those who did not, thereby constituting the control group.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Missing data were not imputed; no per-arm counts of missing data reported
Missing data were not imputed.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Daily life and health overall
Overall symptoms1 study · 57 people took Palmitoylethanolamide (PEA) Improvement C
Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).
Compared with another group, not randomised98 in the study · 3 months · 600 mg, twice a day
Overall symptoms improved more than in the comparison group.
The evidence is very uncertain about the effect of palmitoylethanolamide (PEA) on overall symptoms in long COVID. Improvement · very low certainty C
- Serious risk of bias (ROBINS-I)
See the 1 study
-
- People in the study
- 98 in the study
- Dose
- 600 mg, twice a day
- Outcome
- global improvement predicted by m/umPEA (multivariable logistic regression)
- Effect
- better
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age, sex and neuropsychiatric status prior to therapy; separate models also included SARC-F, FSS, VAS-general, VAS-pain and ZSDS at 3 months
m/umPEA treatment emerged as being a significant predictor of global improvement independently of age, sex and neuropsychiatric status prior to therapy
- Selection of participants
- Moderate. comparison group: Non-randomised; patients who refused m/umPEA served as controls
Patients who chose to receive the proposed treatment were compared to those who did not, thereby constituting the control group.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Missing data were not imputed; no per-arm counts of missing data reported
Missing data were not imputed.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Quality of life1 study · 57 people took Palmitoylethanolamide (PEA) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.
Compared with another group, not randomised98 in the study · 3 months · 600 mg, twice a day
No clear difference in quality of life.
The evidence is very uncertain about the effect of palmitoylethanolamide (PEA) on quality of life in long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
See the 1 study
-
- People in the study
- 98 in the study
- Dose
- 600 mg, twice a day
- Outcome
- ΔVAS visual analog scale
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age, sex and neuropsychiatric status prior to therapy; separate models also included SARC-F, FSS, VAS-general, VAS-pain and ZSDS at 3 months
m/umPEA treatment emerged as being a significant predictor of global improvement independently of age, sex and neuropsychiatric status prior to therapy
- Selection of participants
- Moderate. comparison group: Non-randomised; patients who refused m/umPEA served as controls
Patients who chose to receive the proposed treatment were compared to those who did not, thereby constituting the control group.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Missing data were not imputed; no per-arm counts of missing data reported
Missing data were not imputed.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
600 mg at the start
- 2Raise
Raised step by step in 1 of 3 studies
- 3Top dose
Most often 600 mg (2 of 3 studies)
Doses across 3 studies
600 to 600 mg. One study of 1 people went up to 1200 mg.
Each study’s dose, as printed
- 600 mg two times daily, for about 3 months The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort Study. (2022)
- 600 mg, twice a day Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors. (2024)
- 600 mg/day, later increased to 900 mg/day and 1200 mg/day Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections. (2026)
All papers
- Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors.2024 · compared with another group · 98 in the study
Summary
This retrospective observational substudy of the COVID-BioB study was conducted at a post-COVID-19 outpatient clinic at San Raffaele University Hospital in Milan, Italy. It asked whether micronized/ultramicronized palmitoylethanolamide (m/umPEA) improves neuropsychiatric sequelae in COVID-19 survivors. A total of 98 patients evaluated between February and August 2021 were offered m/umPEA 600 mg orally twice daily for 3 months; 57 accepted and 41 refused and served as controls. Both groups were reassessed at 3 and 6 months with the ZSDS for depression, FSS and SARC-F for fatigue, VAS-pain for chronic pain and VAS-general for subjective well-being. Global improvement was reached in 14 (24.6%) PEA patients and 3 (7.3%) non-PEA patients (P < 0.05). ZSDS and FSS scores decreased in the PEA group and increased in the non-PEA group (both P < 0.05). ZSDS improvement occurred in 29 (50.9%) versus 11 (26.8%) and FSS improvement in 22 (38.6%) versus 6 (14.6%), both P=0.020. No between-group differences were found for VAS-general, VAS-pain or SARC-F. Side effects and withdrawals were not reported. The authors state the study was retrospective, non-randomised, used treatment refusers as controls, had a limited sample size and an arbitrarily established treatment duration.
- Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
- The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort Study.2022 · no comparison group · 33 in the study
Summary
This single-center open-label pre–post single-arm retrospective cohort study enrolled 33 patients with long COVID at a neurological outpatient clinic in Messina, Italy, screened from August 2020 to September 2021. The 33 patients included 10 male and 23 female patients, mean age 47.8 ± 12.4 years. All were treated with PEA 600 mg two times daily for about 3 months; there was no control group. Functional sequelae were assessed with the post-COVID-19 Functional Status (PCFS) scale before treatment (T0) and after 3 months (T1). Most patients obtained a significant improvement in PCFS score (p = 0.0000) after treatment with PEA. The authors also reported a substantial difference in PCFS score between hospitalized and home care groups at baseline and after treatment. In a smoker/non-smoker comparison, the HSm group had PCFS 3.8 ± 0.4 vs. 2.6 ± 0.5 at T0 and 2.2 ± 1.3 vs. 0.4 ± 0.5 at T1 versus NhNSm, with statistically significant differences. All patients completed treatment without any side effects. Limitations stated were the retrospective design, relatively small sample size, and absence of a control group.
- Utilising Continuous HRV Biofeedback Data for Autonomic Nervous System Regulation in ME/CFS Relapse Management2026 · case report · 1 in the study · preprint
Summary
This case report describes one patient with ME/CFS for relapse management in standard client sessions who used continuous heart rate variability (C-HRV) biofeedback with an ECG-grade Firstbeat Life device, health coaching and HRV specialist interpretation for an 11-week intervention, alongside pacing, sleep optimisation, task modification and autonomic regulation strategies. There was no comparison group. The paper reports within-patient changes from baseline to 11 weeks: baseline HRV (RMSSD) rose from 24 ms to 33 ms (+37.5%); Sleep Quality Score from 37/100 to 56/100 (+51.4%); Stress and Recovery Balance Score from 23/100 to 48/100 (+108.7%); and Subjective Wellbeing from 24% to 34% (+41.7%). On the Firstbeat Wellbeing survey, 'I feel that I sleep enough' was 40% at Week 1 and 80% at Week 11 (difference 40); 'I don't feel stressed' was 80% and 80% (0); 'My days include breaks and time for recovery' 80% and 100% (20); 'I feel alert and energetic most of the time' 20% and 40% (40); 'I feel well at the moment' 20% and 40% (60). Harms reported included a sharp drop in overall HRV and near-total absence of nocturnal PNS recovery during a 10-day low dose naltrexone trial, and a complete lack of PNS recovery during sleep on three separate palmitoylethanolamide trials; a severe immune flare occurred immediately after the 11-week intervention. Withdrawals for harms were not reported. The authors state the findings are from a single case (N=1) and may not be representative.
- Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections.2026 · combination: given with other treatments · 1 in the study
Summary
This case report describes one 48-year-old woman in Belo Horizonte, Minas Gerais, Brazil, followed at the Carlos Prates Health Center as part of VITA Monitoring. She had ME/CFS diagnosed in early 2023 and POTS diagnosed later that year after SARS-CoV-2 infection in January 2022, with PCC persisting over three years. Her regimen included pyridostigmine bromide 60 mg every 12 hours, duloxetine hydrochloride 60 mg/day (later 30 mg/day), naltrexone 2 mg/day, bupropion 300 mg/day, palmitoylethanolamide 600 mg/day (later 900 mg/day and 1200 mg/day), vitamin C 1 g/day, Omega-3, pacing, hydroxyzine hydrochloride 25 mg/day, methylprednisolone 125 mg/day for three days, and vitamin B12 1 mg/day. Follow-up was baseline (V1) and evaluations after one month (1M), three months (3M), six months (6M), and twelve months (12M). There was no comparison group and no randomisation. The report states partial improvement in fatigue, orthostatic symptoms, and memory, but worsening of hair loss; worsening of symptoms after starting light walks (10 minutes/day); and treatment responses that were partial and fluctuating, with no objective biomarkers available to quantify them. Final assessment in mid-2025 indicated partial, fluctuating symptom response and persistent functional impairment. Harms reported were worsening hair loss and worsening symptoms after starting light walks; withdrawals for harms were not reported. Table 1 presents anthropometric, vital-sign, and handgrip strength measurements descriptively; the authors state changes should not be interpreted as evidence of a treatment effect.
- Exploring the Potential of Dietary Supplements to Alleviate Pain Due to Long COVID.2025 · review
Summary
This review explored dietary supplements for pain due to long COVID. It was a review, not a randomised trial; it had no comparison group, and the review itself did not report enrollment, setting, or follow-up. It summarized studies in long COVID or post-COVID syndrome, including studies with 60, 33, 69, 1, 463, 39, 51, 80, 53, 20, and 12 participants. Treatments included acetyl-l-carnitine 500 mg/day, palmitoylethanolamide 600 mg twice daily, PEA-LUT 770 mg, SIM01, VSL#3®, a vitamin D–containing supplement, vitamin D, marine oil enriched in SPMs, a multinutrient supplement, NAC plus guanfacine, and metformin. Durations reported in the recorded findings included 2 weeks, 4 weeks, 6 months, and 10 months. Measured outcomes included pain, persistent post-COVID symptoms, smell recovery, fatigue, memory loss, concentration, gastrointestinal upset, general unwellness, cognitive abilities, physical functioning, anxiety, depression, and long COVID risk. Findings included improvements in pain, fatigue, cognitive symptoms, smell, and some quality-of-life domains; one report noted no improvement in anxiety, depression, performance, or somatization. Recorded side effects were minimal side effects with vitamin D and mild adverse events with LDN; another recorded harms statement concerned antidepressants, and 19 participants discontinued because of adverse events (12 gabapentin, 7 placebo). The authors stated that clinical experience in long COVID-associated pain is still limited.
- Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review.2025 · review
Summary
This scoping review asked which therapeutic agents can be used for post-acute sequelae of COVID-19 (PASC). The authors searched PubMed, Embase, and the Cochrane library for English studies published between January 1, 2020, and July 22, 2024; 413 studies were identified and 39 were included. The review did not report a total number of participants. Included reports measured symptoms such as fatigue, pain, cognitive function, olfactory function, pulmonary function, PASC incidence, hospitalization, and death. For metformin, among 1126 patients observed for nine months, 93 (9.3%) reported PASC, with a hazard ratio of 0.59 (95% CI 0.39–0.89; p = 0.012). Low-dose naltrexone showed a hazard ratio of 5.04 for improvement versus physical therapy alone among 108 patients (p = 0.02), and 52–67% of patients in observational studies reported improvements. In a randomized study of 30 patients with PASC and lung fibrosis, nintedanib and pirfenidone improved pulmonary function, 6MWT distance, and oxygen saturation over 12 weeks; nintedanib was associated with diarrhea (80%) and nausea/vomiting (66.6%). The STOP-PASC trial of a 15-day NMV-r course failed to show significant benefit. Ivermectin had no effect on PASC incidence in COVID-OUT, and remdesivir randomized trials showed no clear long-term benefit. The authors state limitations include heterogeneity of PASC symptoms and limited robust evidence.